TD Asset Management
LKFT

TD Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

TD Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,900
Closed -$395K – 1442
2022
Q4 		$395K Hold
8,900
– – ﹤0.01% 1324
2022
Q3 		$376K Buy
+8,900
New +$456K ﹤0.01% 1341

Other funds holding LKFT

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TD Asset Management's LKFT Position: Q1 2023 in Review

TD Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2023, closing a stake of 8,900 shares — an estimated $395K sold.

TD Asset Management first reported a position in LKFT in Q3 2022 and held it in 2 quarters. The position peaked at $395K in Q4 2022. 75 funds tracked by Wall St. Rank hold LKFT as of Q1 2023.

  • TD Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2023 after selling out during the quarter.
  • TD Asset Management sold 8,900 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2023, an estimated $395K.
  • TD Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2022 and held it in 2 quarters.
  • TD Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $395K in Q4 2022.
  • 75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2023.

Based on TD Asset Management's 13F filing for Q1 2023, filed 10 May 2023.